Apellis Pharmaceuticals enters into senior secured credit facility
…
38,515€
1,12%
Echtzeit-Aktienkurs Apellis Pharmaceuticals
Bid:
Ask:
Nachrichten zur Apellis Pharmaceuticals Aktie
Earnings call: Apellis Pharmaceuticals Q1 2024 financials show growth By Investing.com
Earnings call: Apellis Pharmaceuticals Q1 2024 financials show growth…
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Apellis Pharmaceuticals stock falls following Mizuho comments, price target cut By Investing.com
Apellis Pharmaceuticals stock falls following Mizuho comments, price target cut…
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the European…
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Apellis Pharmaceuticals director sells over $1 million in company stock By Investing.com
Apellis Pharmaceuticals director sells over $1 million in company stock…
Apellis Pharmaceuticals officer sells $564k in company stock By Investing.com
Apellis Pharmaceuticals officer sells $564k in company stock…
Apellis Pharmaceuticals VP sells over $10k in company stock By Investing.com
Apellis Pharmaceuticals VP sells over $10k in company stock…
Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations…
UBS raises Apellis Pharmaceuticals shares target on strong outlook By Investing.com
UBS raises Apellis Pharmaceuticals shares target on strong outlook…
Apellis Pharmaceuticals, Inc. (APLS) Q4 and Full Year 2023 Earnings Call Transcript
…
Apellis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Apellis Pharmaceuticals Q4 2023 Earnings Preview
…
Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
…
Apellis Pharmaceuticals upgraded to buy by Jefferies By Investing.com
Apellis Pharmaceuticals upgraded to buy by Jefferies…
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) …
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) …
Apellis Pharmaceuticals expects European regulators to reject eye disease drug
Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares fell more than 22% after it said it expects European regulators to reject its therapeutic…
Apellis Pharmaceuticals stock just tumbled. Here’s why By Investing.com
© Reuters. Apellis Pharmaceuticals (APLS) stock just tumbled. Here’s why Apellis Pharma (APLS) stock experienced a sharp pre-market decline following…
: Apellis Pharmaceuticals’ stock slides 14% after company gets negative trend vote for eye treatment in Europe
Apellis Pharmaceuticals Inc.’s stock APLS tumbled 14% early Thursday, after the company said it’s been informed of a negative trend…
Apellis Pharmaceuticals’ stock slides 14% after company gets negative trend vote for eye treatment in Europe
…
Apellis Pharmaceuticals stock just tumbled. Heres why By Investing.com
Apellis Pharmaceuticals stock just tumbled. Heres why…
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi today presented post…
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)…
Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution
…
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will…
Apellis Pharmaceuticals tumbles as Citron Research says legal action seems imminent By Investing.com
Apellis Pharmaceuticals tumbles as Citron Research says legal action seems imminent…
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript
…
Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation
…
Apellis Pharmaceuticals Q3 2023 Earnings Preview
…
Investigation Alert Apellis Pharmaceuticals, KeyCorp, RTX Corporation, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) …
Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earnings
…
Apellis Pharmaceuticals: Eye Watering, Roller-Coaster Ride In 2023 To Date - Im Hitting Pause
…
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet…
Sobi announces positive Phase 2 NOBLE results of pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G
· After 12 weeks, 50% of patients treated with pegcetacoplan showed a reduction in C3c staining by two or more…
Apellis Pharmaceuticals raised at JPMorgan as improving Syfovre fundamentals will be upside driver for shares By Investing.com
Apellis Pharmaceuticals raised at JPMorgan as improving Syfovre fundamentals will be upside driver for shares…
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today provided an update on…
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food…
Lifshitz Law PLLC Announces Investigations of Apellis Pharmaceutics, Inc. (NASDAQ: APLS), RTX Corp. (NYSE: RTX), Live Nation Entertainment, Inc. (NYSE: LYV), and KeyCorp (NYSE: KEY)
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)…
APLS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS
CEDARHURST, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:…
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
LOS ANGELES, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the…